We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · April 27, 2021

Ranibizumab vs Aflibercept for Macular Oedema in Branch RVO

The British Journal of Ophthalmology

 

Additional Info

The British Journal of Ophthalmology
Twelve-Month Outcomes of Ranibizumab Versus Aflibercept for Macular Oedema in Branch Retinal Vein Occlusion: Data From the FRB! Registry
Br J Ophthalmol 2021 Mar 12;[EPub Ahead of Print], AR Hunt, V Nguyen, CP Creuzot-Garcher, S Alforja, PH Gabrielle, J Zarranz-Ventura, M Guillemin, S Fraser-Bell, RP Casaroli Marano, J Arnold, IL McAllister, L O'Toole, MC Gillies, D Barthelmes, H Mehta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading